Literature DB >> 7863832

Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer.

M Koutsilieris1, A Sourla, G Pelletier, C J Doillon.   

Abstract

We developed a three-dimensional type I collagen gel cell culture system that allows coculturing of human MG-63 osteoblast-like cells and various human cancer cells. Inoculation of human PC-3 metastatic prostate cancer cells into this type I collagen gel containing human MG-63 osteoblast-like cells produced an osteoblastic-like reaction that presented as an increased number of MG-63 cells and increased density of type I collagen around MG-63 cells adjacent to inoculated PC-3 cells by microscope analysis. Under identical experimental conditions, inoculation of cell-free medium, human KLE endometrial adenocarcinoma cells, and Calu-1 lung cancer cells did not produce this blastic-like reaction. In situ hybridization documented the uniform expression of insulin-like growth factor I (IGF-I) and of urokinase-type plasminogen activator (uPA) mRNA in MG-63 and PC-3 cells separately cultured in this substrata. The uniform expression of uPA was also documented by immunocytochemistry using a monoclonal and a polyclonal antihuman uPA antibody. The relative expression of uPA was higher in PC-3 cells than in MG-63, KLE, and Calu-1 cancer cells. We conclude that this novel cell culture system may become a useful model to study the pathophysiology of the osteoblastic reaction in vitro.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7863832     DOI: 10.1002/jbmr.5650091120

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  8 in total

Review 1.  Three-dimensional cultures of prostatic cells: tissue models for the development of novel anti-cancer therapies.

Authors:  K C O'Connor
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

Review 2.  Bone metastasis in prostate cancer: emerging therapeutic strategies.

Authors:  Justin Sturge; Matthew P Caley; Jonathan Waxman
Journal:  Nat Rev Clin Oncol       Date:  2011-05-10       Impact factor: 66.675

3.  Insulinlike growth factor-1Ec (MGF) expression in eutopic and ectopic endometrium: characterization of the MGF E-peptide actions in vitro.

Authors:  Dimitrios S Milingos; Anastassios Philippou; Athanassios Armakolas; Efstathia Papageorgiou; Antigone Sourla; Athanassios Protopapas; Anthi Liapi; Aris Antsaklis; Minas Mastrominas; Michael Koutsilieris
Journal:  Mol Med       Date:  2010-09-14       Impact factor: 6.354

4.  The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer.

Authors:  Elena Theophanous; Constantina Petraki; Andreas Scorilas; Vassilios Komborozos; George Veloudis; Jozsef L Varga; Marta Zarandi; Andrew V Schally; Michael Koutsilieris
Journal:  Mol Med       Date:  2009-04-15       Impact factor: 6.354

5.  Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors.

Authors:  M Koutsilieris; C Reyes-Moreno; I Choki; A Sourla; C Doillon; N Pavlidis
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

6.  Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells.

Authors:  Efstathia Papageorgiou; Nea Pitulis; Menelaos Manoussakis; Peter Lembessis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

7.  Characterization of human osteoblastic cells: influence of the culture conditions.

Authors:  A Rattner; O Sabido; C Massoubre; F Rascle; J Frey
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997 Nov-Dec       Impact factor: 2.723

8.  Fibrous Hydrogels for Cell Encapsulation: A Modular and Supramolecular Approach.

Authors:  Małgorzata K Włodarczyk-Biegun; Kambiz Farbod; Marc W T Werten; Cornelis J Slingerland; Frits A de Wolf; Jeroen J J P van den Beucken; Sander C G Leeuwenburgh; Martien A Cohen Stuart; Marleen Kamperman
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.